Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1997 Apr;6(2):147–153. doi: 10.1080/09629359791857

Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM

I Drucker 1, A Klajman 1,✉, M Revel 2, Y Manor 3, S Ben-Efraim 4, D Novick 2
PMCID: PMC2365853  PMID: 18472849

Abstract

Interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) were detected in supernatants of cultures of B chronic lymphatic leukaemia (CLL) lymphocytes. Phorbol-12-myristate 13 acetate (PMA) caused a decrease in the levels of IL-6 in 14 out of 16 cultures and an increase in levels of sIL6R in all 15 cases. The effect of pokeweed mitogen (PWM) was variable and not significant. The levels of IL-6 were below the detection limit (60 pg/ml) in sera of 13 CLL patients whereas sIL-6R was detected (13 ng/ml to 97 ng/ml) in the 13 sera. IL6 was not detected in cultures of unstimulated or stimulated with PMA or PWM normal human B cells. Levels of sIL-6R were minimal in cultures of normal B lymphocytes and were increased in PMA stimulated cultures. The results are consistent with the view that B-CLL cells produce spontaneously IL-6 which could act in an autocrine fashion to cause shedding of surface IL-6R and account for the correlation found between serum levels of sIL-6R and B-CLL lymphocyte numbers. The fall in levels of IL-6 in PMA stimulated CLL cultures might express masking or degradation of IL-6 after combination with the receptor.

Full Text

The Full Text of this article is available as a PDF (217.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biondi A., Rossi V., Bassan R., Barbui T., Bettoni S., Sironi M., Mantovani A., Rambaldi A. Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia. Blood. 1989 Apr;73(5):1279–1284. [PubMed] [Google Scholar]
  2. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed] [Google Scholar]
  3. Farkas R., Ben-Efraim S., Manor Y., Zan-Bar I., Klajman A. Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures. Cancer Immunol Immunother. 1991;34(3):181–185. doi: 10.1007/BF01742310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Farkas R., Manor Y., Klajman A. Long-term cultures of chronic lymphocytic leukemia B cells generate B suppressor cells. Clin Immunol Immunopathol. 1987 Feb;42(2):171–182. doi: 10.1016/0090-1229(87)90004-3. [DOI] [PubMed] [Google Scholar]
  5. Garman R. D., Jacobs K. A., Clark S. C., Raulet D. H. B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7629–7633. doi: 10.1073/pnas.84.21.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hirano T., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T., Kashiwamura S., Nakajima K., Koyama K., Iwamatsu A. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986 Nov 6;324(6092):73–76. doi: 10.1038/324073a0. [DOI] [PubMed] [Google Scholar]
  7. Horii Y., Muraguchi A., Suematsu S., Matsuda T., Yoshizaki K., Hirano T., Kishimoto T. Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells. J Immunol. 1988 Sep 1;141(5):1529–1535. [PubMed] [Google Scholar]
  8. Kishimoto T., Akira S., Taga T. IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol. 1992 Apr;14(3):431–438. doi: 10.1016/0192-0561(92)90173-i. [DOI] [PubMed] [Google Scholar]
  9. Kishimoto T. The biology of interleukin-6. Blood. 1989 Jul;74(1):1–10. [PubMed] [Google Scholar]
  10. Levy Y., Fermand J. P., Brouet J. C. Differential effects of low and high concentrations of interleukin 6 on human B cells. Eur J Immunol. 1990 Nov;20(11):2389–2393. doi: 10.1002/eji.1830201105. [DOI] [PubMed] [Google Scholar]
  11. Maliszewski C. R., Fanslow W. C. Soluble receptors for IL-1 and IL-4: biological activity and therapeutic potential. Trends Biotechnol. 1990 Nov;8(11):324–329. doi: 10.1016/0167-7799(90)90213-h. [DOI] [PubMed] [Google Scholar]
  12. Matsuzaki N., Saji F., Kameda T., Yoshizaki K., Okada T., Sawai K., Tanizawa O. In vitro and in vivo production of interleukin-6 by fetal mononuclear cells. Clin Immunol Immunopathol. 1990 May;55(2):305–314. doi: 10.1016/0090-1229(90)90106-z. [DOI] [PubMed] [Google Scholar]
  13. Müllberg J., Schooltink H., Stoyan T., Günther M., Graeve L., Buse G., Mackiewicz A., Heinrich P. C., Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993 Feb;23(2):473–480. doi: 10.1002/eji.1830230226. [DOI] [PubMed] [Google Scholar]
  14. Navarro S., Debili N., Le Couedic J. P., Klein B., Breton-Gorius J., Doly J., Vainchenker W. Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. Blood. 1991 Feb 1;77(3):461–471. [PubMed] [Google Scholar]
  15. Nordan R. P., Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 1986 Aug 1;233(4763):566–569. doi: 10.1126/science.3726549. [DOI] [PubMed] [Google Scholar]
  16. Novick D., Cohen B., Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett. 1992 Dec 21;314(3):445–448. doi: 10.1016/0014-5793(92)81523-o. [DOI] [PubMed] [Google Scholar]
  17. Novick D., Engelmann H., Revel M., Leitner O., Rubinstein M. Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma. 1991 Feb;10(1):137–146. doi: 10.1089/hyb.1991.10.137. [DOI] [PubMed] [Google Scholar]
  18. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989 Oct 1;170(4):1409–1414. doi: 10.1084/jem.170.4.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Novick D., Eshhar Z., Revel M., Mory Y. Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity. Hybridoma. 1989 Oct;8(5):561–567. doi: 10.1089/hyb.1989.8.561. [DOI] [PubMed] [Google Scholar]
  20. Novick D., Shulman L. M., Chen L., Revel M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine. 1992 Jan;4(1):6–11. doi: 10.1016/1043-4666(92)90029-q. [DOI] [PubMed] [Google Scholar]
  21. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  22. Rieckmann P., D'Alessandro F., Nordan R. P., Fauci A. S., Kehrl J. H. IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. J Immunol. 1991 May 15;146(10):3462–3468. [PubMed] [Google Scholar]
  23. Yoshizaki K., Nakagawa T., Fukunaga K., Tseng L. T., Yamamura Y., Kishimoto T. Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol. 1984 Jun;132(6):2948–2954. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES